Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy.

Trial Profile

Treatment Optimization of Newly Diagnosed Ph/BCR-ABL Positive Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase With Nilotinib vs. Nilotinib Plus Interferon Alpha Induction and Nilotinib or Interferon Alpha Maintenance Therapy.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Nilotinib (Primary) ; Peginterferon alfa-2b
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms TIGER
  • Most Recent Events

    • 21 Aug 2017 Planned End Date changed from 1 Dec 2020 to 1 Dec 2022.
    • 21 Aug 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2020.
    • 21 Aug 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top